A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

@article{Toledo2001API,
  title={A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.},
  author={H{\'e}ctor Toledo and Alberto Baly and Oswaldo de Castro and Sonia Resik and Jos{\'e} Laferte and Francisco Rolo and Leonor M Navea and Leonor I Lobaina and Oswaldo R Cruz and Jesus Miguez and Teresita Serrano and Beatriz de la C Sierra and Luis Perez and Manuel Ricardo and Marta Dubed and A L Lubi{\'a}n and Michael Blanco and J. C. M{\`i}ll{\`a}n and Antonio Ortega and Enrique Mantilla Iglesias and Eduardo Pent{\'o}n and Zenia Martin and J. Zu{\~n}iga P{\'e}rez and Manuel Rodr{\'i}guez D{\'i}az and C. Armando Duarte},
  journal={Vaccine},
  year={2001},
  volume={19 30},
  pages={4328-36}
}
A phase I clinical trial was performed to examine the safety and immunogenicity of a multi-epitope polypeptide comprising the central 15 amino acids of the V3 loop from six HIV-1 isolates. This protein called TAB9 was emulsified in Montanide ISA720 (Seppic, Paris) and administered intramuscularly at doses of 0, 0.2 and 1 mg to 24 healthy, HIV-1 seronegative… CONTINUE READING